Cargando…

Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice

INTRODUCTION: The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is considered to be a potential therapeutic agent for prevention of cerebral ischemia. Ischemia is a most common cause of death after heart attack and cancer causing major negative social and economic consequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hori, Motohide, Nakamachi, Tomoya, Rakwal, Randeep, Shibato, Junko, Ogawa, Tetsuo, Aiuchi, Toshihiro, Tsuruyama, Tatsuaki, Tamaki, Keiji, Shioda, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526409/
https://www.ncbi.nlm.nih.gov/pubmed/23176072
http://dx.doi.org/10.1186/1742-2094-9-256
_version_ 1782253553808572416
author Hori, Motohide
Nakamachi, Tomoya
Rakwal, Randeep
Shibato, Junko
Ogawa, Tetsuo
Aiuchi, Toshihiro
Tsuruyama, Tatsuaki
Tamaki, Keiji
Shioda, Seiji
author_facet Hori, Motohide
Nakamachi, Tomoya
Rakwal, Randeep
Shibato, Junko
Ogawa, Tetsuo
Aiuchi, Toshihiro
Tsuruyama, Tatsuaki
Tamaki, Keiji
Shioda, Seiji
author_sort Hori, Motohide
collection PubMed
description INTRODUCTION: The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is considered to be a potential therapeutic agent for prevention of cerebral ischemia. Ischemia is a most common cause of death after heart attack and cancer causing major negative social and economic consequences. This study was designed to investigate the effect of PACAP38 injection intracerebroventrically in a mouse model of permanent middle cerebral artery occlusion (PMCAO) along with corresponding SHAM control that used 0.9% saline injection. METHODS: Ischemic and non-ischemic brain tissues were sampled at 6 and 24 hours post-treatment. Following behavioral analyses to confirm whether the ischemia has occurred, we investigated the genome-wide changes in gene and protein expression using DNA microarray chip (4x44K, Agilent) and two-dimensional gel electrophoresis (2-DGE) coupled with matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS), respectively. Western blotting and immunofluorescent staining were also used to further examine the identified protein factor. RESULTS: Our results revealed numerous changes in the transcriptome of ischemic hemisphere (ipsilateral) treated with PACAP38 compared to the saline-injected SHAM control hemisphere (contralateral). Previously known (such as the interleukin family) and novel (Gabra6, Crtam) genes were identified under PACAP influence. In parallel, 2-DGE analysis revealed a highly expressed protein spot in the ischemic hemisphere that was identified as dihydropyrimidinase-related protein 2 (DPYL2). The DPYL2, also known as Crmp2, is a marker for the axonal growth and nerve development. Interestingly, PACAP treatment slightly increased its abundance (by 2-DGE and immunostaining) at 6 h but not at 24 h in the ischemic hemisphere, suggesting PACAP activates neuronal defense mechanism early on. CONCLUSIONS: This study provides a detailed inventory of PACAP influenced gene expressions and protein targets in mice ischemic brain, and suggests new targets for thereaupetic interventions.
format Online
Article
Text
id pubmed-3526409
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35264092012-12-20 Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice Hori, Motohide Nakamachi, Tomoya Rakwal, Randeep Shibato, Junko Ogawa, Tetsuo Aiuchi, Toshihiro Tsuruyama, Tatsuaki Tamaki, Keiji Shioda, Seiji J Neuroinflammation Research INTRODUCTION: The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is considered to be a potential therapeutic agent for prevention of cerebral ischemia. Ischemia is a most common cause of death after heart attack and cancer causing major negative social and economic consequences. This study was designed to investigate the effect of PACAP38 injection intracerebroventrically in a mouse model of permanent middle cerebral artery occlusion (PMCAO) along with corresponding SHAM control that used 0.9% saline injection. METHODS: Ischemic and non-ischemic brain tissues were sampled at 6 and 24 hours post-treatment. Following behavioral analyses to confirm whether the ischemia has occurred, we investigated the genome-wide changes in gene and protein expression using DNA microarray chip (4x44K, Agilent) and two-dimensional gel electrophoresis (2-DGE) coupled with matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS), respectively. Western blotting and immunofluorescent staining were also used to further examine the identified protein factor. RESULTS: Our results revealed numerous changes in the transcriptome of ischemic hemisphere (ipsilateral) treated with PACAP38 compared to the saline-injected SHAM control hemisphere (contralateral). Previously known (such as the interleukin family) and novel (Gabra6, Crtam) genes were identified under PACAP influence. In parallel, 2-DGE analysis revealed a highly expressed protein spot in the ischemic hemisphere that was identified as dihydropyrimidinase-related protein 2 (DPYL2). The DPYL2, also known as Crmp2, is a marker for the axonal growth and nerve development. Interestingly, PACAP treatment slightly increased its abundance (by 2-DGE and immunostaining) at 6 h but not at 24 h in the ischemic hemisphere, suggesting PACAP activates neuronal defense mechanism early on. CONCLUSIONS: This study provides a detailed inventory of PACAP influenced gene expressions and protein targets in mice ischemic brain, and suggests new targets for thereaupetic interventions. BioMed Central 2012-11-23 /pmc/articles/PMC3526409/ /pubmed/23176072 http://dx.doi.org/10.1186/1742-2094-9-256 Text en Copyright ©2012 Hori et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hori, Motohide
Nakamachi, Tomoya
Rakwal, Randeep
Shibato, Junko
Ogawa, Tetsuo
Aiuchi, Toshihiro
Tsuruyama, Tatsuaki
Tamaki, Keiji
Shioda, Seiji
Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title_full Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title_fullStr Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title_full_unstemmed Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title_short Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
title_sort transcriptomics and proteomics analyses of the pacap38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526409/
https://www.ncbi.nlm.nih.gov/pubmed/23176072
http://dx.doi.org/10.1186/1742-2094-9-256
work_keys_str_mv AT horimotohide transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT nakamachitomoya transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT rakwalrandeep transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT shibatojunko transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT ogawatetsuo transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT aiuchitoshihiro transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT tsuruyamatatsuaki transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT tamakikeiji transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice
AT shiodaseiji transcriptomicsandproteomicsanalysesofthepacap38influencedischemicbraininpermanentmiddlecerebralarteryocclusionmodelmice